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SHORT REPORT
Poor glycaemic control is associated 
with reduced exercise performance and oxygen 
economy during cardio-pulmonary exercise 
testing in people with type 1 diabetes
Othmar Moser1,2* , Max L. Eckstein1,2, Olivia McCarthy1,2, Rachel Deere1,2, Stephen C. Bain1, Hanne L. Haahr3, 
Eric Zijlstra4 and Richard M. Bracken1,2
Abstract 
Background: To explore the impact of glycaemic control  (HbA1c) on functional capacity during cardio-pulmonary 
exercise testing in people with type 1 diabetes.
Methods: Sixty-four individuals with type 1 diabetes (age: 34 ± 8 years; 13 females,  HbA1c: 7.8 ± 1% (62 ± 13 mmol/
mol), duration of diabetes: 17 ± 9 years) performed a cardio-pulmonary cycle ergometer exercise test until volitional 
exhaustion. Stepwise linear regression was used to explore relationships between  HbA1c and cardio-respiratory data 
with p ≤ 0.05. Furthermore, participants were divided into quartiles based on  HbA1c levels and cardio-respiratory data 
were analysed by one-way ANOVA. Multiple regression analysis was performed to explore the relationships between 
changes in time to exhaustion and cardio-respiratory data. Data were adjusted for confounder.
Results: HbA1c was related to time to exhaustion and oxygen consumption at the power output elicited at the sub-
maximal threshold of the heart rate turn point (r = 0.47,  R2 = 0.22, p = 0.03). Significant differences were found at 
time to exhaustion between QI vs. QIV and at oxygen consumption at the power output elicited at the heart rate turn 
point between QI vs. QII and QI vs. QIV (p < 0.05). Changes in oxygen uptake, power output and in oxygen consump-
tion at the power output elicited at the heart rate turn point and at maximum power output explained 55% of the 
variance in time to exhaustion (r = 0.74,  R2 = 0.55, p < 0.01).
Conclusions: Poor glycaemic control is related to less economical use of oxygen at sub-maximal work rates and an 
earlier time to exhaustion during cardio-pulmonary exercise testing. However, exercise training could have the same 
potential to counteract the influence of poor glycaemic control on functional capacity.
Trial registration NCT01704417. Date of registration: October 11, 2012
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Introduction
Type 1 diabetes (T1D) is associated with an increased 
risk of cardio-vascular disease (CVD) compared to peo-
ple without diabetes. Although regular physical activity 
is encouraged as a cornerstone of good diabetes man-
agement [1, 2], physical inactivity rates remain high [3]. 
Patients often cite low functional capacity and loss of 
metabolic control (short-term and/or long term glycae-
mic disturbances) as barriers to beginning or maintaining 
regular physical activity [4].
Functional capacity, defined as the ability to perform 
aerobic work during maximal exercise testing can be 
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testing. This non-invasive, sensitive test provides an 
assessment of integrative responses of cardiovascular, 
pulmonary and musculoskeletal systems across a sub-
maximal to maximal continuum and can be utilised 
to identify fatigue of cardiovascular or respiratory ori-
gin [5]. Most reported studies in people with T1D have 
assessed maximum cardio-pulmonary values such as the 
peak oxygen uptake  (VO2peak) [6–8].  VO2peak is the high-
est rate of oxygen that can be consumed during exercise 
involving the majority of muscle mass at sea-level and is 
defined by the Fick equation as the product of cardiac 
output and arteriovenous oxygen difference [5]. Achiev-
ing a true  VO2peak requires strong motivation and physi-
cal fitness, but for people with T1D with ‘low exercise 
tolerance’ the perception of exercise-induced pain may 
encourage premature test termination. In addition, the 
presence of diabetes complications such as neuropathy, 
nephropathy and underlying CVD may exacerbate pain 
or damage during exercise and reduce the validity of CPX 
testing in detailing accurate maximum cardio-respira-
tory parameters e.g.  VO2 plateau, maximum heart rate 
 (HRmax).
Most activities in daily life are performed at low-to 
moderate intensity and do not require maximum cardio-
respiratory effort. It may be more relevant in people with 
T1D to explore cardio-respiratory data obtained dur-
ing sub-maximal stages of CPX testing. The rate of oxy-
gen use at sub-maximal exercise intensities provides an 
indication of the economy of use of oxygen for an indi-
vidual to the work rate and has been shown to predict 
endurance performance in healthy individuals [9]. Fur-
thermore, identification of the sub-maximal work rate 
at which there is an increase in use of non-oxidative fuel 
sources (i.e. cellular glycolysis) results in a greater pro-
duction of carbon dioxide  (CO2), pyruvate and lactic acid 
fermentation. Identification of such ‘thresholds’ involv-
ing ventilation, heart rate and/or blood lactate have been 
studied as sub-maximal predictors of endurance capac-
ity in healthy cohorts and in people with chronic disease 
[5]. As an example the heart rate turn point (HRTP), 
which is based on findings from Conconi et al., was sig-
nificantly associated with the second lactate threshold 
[10–13]. This heart rate derived threshold is defined as 
the intersection of two regression lines of the heart rate 
to performance curve between early stages of CPX test-
ing [peri-first lactate turn point  (LTP1)] and maximum 
power output  (Pmax), determined from a second-degree 
polynomial representation satisfying the condition of 
least error squares [14]. However, there is a lack of infor-
mation about their use in people with T1D in predicting 
functional capacity.
Lower maximum cardio-respiratory variables have 
been reported in participants with T1D compared to 
healthy individuals in some studies but not in others [8, 
15]. A review by Baldi et al. [16] shed some light on the 
influence of glycaemic control within people with T1D 
and when compared to healthy individuals. Patients with 
poor glycaemic control demonstrated a lower peak func-
tional capacity than those patients with good glycaemic 
control. No information currently exists on the influence 
of glycaemic control on sub-maximal cardio-respiratory 
parameters obtained from a CPX test. Such information 
might reveal additional insights on the impact of glycae-
mia on the functioning of the cardio-vascular and res-
piratory system and provide further support for the use 
of moderate intensity exercise tests that reduce stress on 
the patient.
The aim of this study was to examine the relationship of 
glycaemic control to sub-maximal and maximum cardio-




Adults (aged 18–45  years, both inclusive) with T1D 
eligible for the study had a body mass index (BMI) of 
18–27 kg/m2, glycated haemoglobin  (HbA1c) level ≤ 9.5% 
(80  mmol/mol) and were performing regular physi-
cal cardiorespiratory exercise during the last 3  months 
before screening. Exclusion criteria included cancer, 
cardiac diseases, supine blood pressure outside the 
range 90–140  mmHg for systolic blood pressure or 
50–90  mmHg for diastolic blood pressure, recurrent 
severe hyperglycaemia or hypoglycaemia unawareness 
and smoking [17]. Sixty-four people with T1D were 
included for analyses (Table 1). Data were extracted from 
a clinical trial (NCT01704417) [17].
Study procedures
After the assessment of eligibility, patients were asked 
to fill in the International Physical Activity Question-
naire (IPAQ) to assess physical activity (MET min/week). 
Patients characteristics, medical history and medications 
were documented in a case report form (CRF). After-
wards, HbA1c was measured via a venous blood sample 
collected from the antecubital vein (Automated Glycohe-
moglobin Analyzer HLC-723G8, Tosoh Europe N.V, Bel-
gium). Immediately before and after CPX testing, venous 
blood was collected to analyse blood glucose concentra-
tion to ensure euglycaemia during CPX testing (Super 
GL Glucose Analyzer, Dr. Müller Gerätebau GmbH, 
Germany). If pre-exercise venous blood glucose concen-
tration was below 4.4  mmol/l carbohydrates were given 
(15–30 g) and if blood glucose concentration was above 
13.9 mmol/l a small bolus correction dose was adminis-
tered. No hypo- (< 3.9 mmol/l) or severe hyperglycaemia 
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(> 19.4 mmol/l) occurred before or during CPX testing. 
The timing of bolus insulin injection was not exactly 
pre-defined, but participants were told to avoid the peak 
action of bolus insulin during CPX testing (this means 
avoiding bolus insulin injections less than 120 min prior 
to the start of CPX testing). Participants performed a 
CPX test until volitional exhaustion on a cycle ergom-
eter (Ergospirometer  PowerCube®-Ergo, Ganshorn 
Medizin Electronic, GER). Participants sat quietly on the 
cycle ergometer for 3 min (0 W) before they started the 
warm-up period of 3 min cycling at a workload of 30 W 
for females and 40 W for males. Then, the workload was 
increased by 30 W for females and 40 W for males every 
3  min until maximum volitional exhaustion. Finally, a 
cool-down period was performed for 1 min.
Measurements
Pulmonary gas exchange variables were collected con-
tinuously by breath-by-breath measurement and then 
averaged over 10  s.  VO2peak was defined as the 1  min 
average in oxygen  (O2) consumption during the high-
est work rate. Heart rate and blood pressure were 
measured continuously via a 12-lead electrocardiogram 
and an automatic sphygmomanometer (Ergospirometer 
 PowerCube®-Ergo, Ganshorn Medizin Electronic, GER).
The non-invasive anaerobic threshold was defined by 
the HRTP [18]. HRTP was demarcated as the intersection 
of two regression lines of the heart rate to performance 
curve between post-warm-up and maximum power out-
put  (Pmax), determined from the second-degree polyno-
mial representation satisfying the condition of least error 
squares [14]. Additionally, the second ventilatory thresh-
old  (VT2) was determined by means of the ventilation/
carbon dioxide (VE/VCO2) slope [19] to control for the 
accuracy of HRTP.
Statistical analysis
Data (10  s average) were expressed as absolute values 
and relative to maximum physiological variables and 
 Pmax. Data were tested for distribution via Shapiro-Wilks 
normality test and non-normal distributed data were 
log transformed. Stepwise linear regression was used to 
explore relationships between glycaemic control  (HbA1c) 
and CPX obtained cardio-respiratory data and perfor-
mance markers with p  ≤  0.05. Data were adjusted for 
sex, age, BMI, blood glucose concentration at the start 
of CPX testing and duration of diabetes. Post hoc power 
analysis for the primary outcome [stepwise linear regres-
sion: dependent variable  HbA1c levels, independent vari-
ables time to exhaustion  (Timemax) and oxygen economy 
at HRTP] resulted in a power (1-beta error probability) 
of 0.96.
Participants were divided into quartiles (Q) based on 
 HbA1c levels, and respective sub-maximal and maximal 
CPX derived cardio-respiratory data and performance 
markers were analysed by one-way analysis of variance 
(ANOVA) followed by a fishers least significant differ-
ence multiple comparison post hoc test (LSD). Multiple 
regression analysis was performed to explore relation-
ships between changes in  Timemax and independent vari-
ables,  VO2peak and oxygen uptake at the heart rate turn 
point  (VO2HRTP), body mass adjusted values of  Pmax and 
power output at the heart rate turn point  (PHRTP) as well 
as oxygen economy at  Pmax  [VO2peak/Pmax (ml/min/W)] 
and at HRTP  [VO2HRTP/PHRTP (ml/min/W)]. All statis-
tics were performed with a standard software package of 
SPSS software version 22 (IBM Corporation, USA) and 
Prism Software version 7.0 (GraphPad, USA).
Results
Exercise performance data
Maximum physiological parameters were found at  HRmax 
of 185 ± 11 b/min,  VO2peak 37 ± 5 ml/kg/min, respiratory 
exchange ratio (RER) 1.22 ± 0.09 and  Pmax 231 ± 47 W. 
No significant differences were found between the HRTP 
Table 1 Participant characteristics given as mean ± SD 
and percentage (%)
Characteristic Total (n = 64)
Age (years) 34 ± 8
Gender
 Female (n; %) 13 (20)
 Male (n; %) 51 (80)
Body mass index (kg/m2) 24 ± 2
Blood pressure (mmHg) 124 ± 17/79 ± 12
Resting heart rate (b/min) 81 ± 12
Duration of diabetes (years) 17 ± 9
HbA1c [% (mmol/mol)] 7.8 ± 1 (62 ± 13)
Total daily dose of insulin (U) 51 ± 15
Type of therapy
 Multiple daily injections (n; %) 47 (78)
 Insulin pump therapy (n; %) 17 (22)
Co-morbidities 14
 Arterial hypertension 6
 Hypothyroidism 5
 Hypercholesterolemia 2
 Hashimoto thyroiditis 1
Medication other than insulin
 ACE inhibitor 6
 Levothyroxine 6
 Statin 2
 Diuretic medication 1
 Calcium channel blocker 1
Physical activity assessed via IPAQ (MET min week) 3086 ± 2736
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and the  VT2 as well as for the comparison of pre- and 
post-exercise blood glucose concentration as given in 
Table 2.
Glycaemic control and functional capacity
As shown in Fig. 1, sex-, age-, BMI-, blood glucose con-
centration at the start of CPX testing- and duration 
of diabetes-adjusted stepwise linear regression model 
revealed that  HbA1c was related to  Timemax and oxygen 
consumption at the power output elicited at the sub-
maximal threshold of the heart rate turn point  (VO2HRTP/
PHRTP) (r = 0.47,  R2 = 0.22, p = 0.03).
Grouped  HbA1c levels and functional capacity
Grouping participants based on quartiles of glycae-
mic control resulted in  HbA1c levels of 6.7  ±  0.5% 
(49  ±  6  mmol/mol) for quartile I, 7.6  ±  0.1% 
(60  ±  1  mmol/mol) for quartile II, 8.0  ±  0.1% 
(63  ±  1  mmol/mol) for quartile III and 9.1  ±  0.6% 
(76  ±  7  mmol/mol) for quartile IV (p  <  0.01). No sig-
nificant differences were found for physical activity 
(p  =  0.68), resting HR (p  =  0.42), systolic blood pres-
sure (p =  0.18) and diastolic blood pressure (p =  0.83) 
between groups.
Significant differences were found at  Timemax between 
QI vs. QIV (mean difference 2.5 ± 1.0 min, p = 0.02) and 
at  VO2HRTP/PHRTP between QI vs. QII (−  1.5 ±  0.6  ml/
min/W, p  =  0.02) and QI vs QIV (−  1.6  ±  0.71  ml/
min/W, p = 0.01) (Fig. 2).
White bar  =  QI  (HbA1c 6.  ±  0.5%; 4  ±  6  mmol/
mol), bright-grey bar  =  QII  (HbA1c 7.  ±  0.1%; 
60  ±  1  mmol/mol), dark-grey bar  =  QIII  (HbA1c 
8. ± 0.1%; 6 ± 1 mmol/mol) and black bar = QIV  (HbA1c 
9.1 ± 0.6%; 7 ± 7 mmol/mol). Values are given as mean 
and SD. “*” represents p ≤ 0.05.
Relationships of time to exhaustion and cardio‑pulmonary 
responses during CPX testing
Multiple regression analysis revealed that changes in 
 VO2peak,  VO2HRTP,  Pmax,  PHRTP,  VO2HRTP/PHRTP as well 
as  VO2peak/Pmax constitute independent predictors of 
 Timemax (r  =  0.74, p  <  0.01) and those variables could 
explain 55% of the alteration in  Timemax.
Discussion
This study demonstrated an important relationship 
between glycaemic control and the cardio-respiratory 
responses to CPX testing in people with T1D. Exercise 
Table 2 Comparison of the anaerobic thresholds derived from HRTP and  VT2 as well as pre- and post-exercise blood glu-
cose levels
Results are given as mean ± SD
HRTP VT2 p value
VO2 (l/min) 2.09 ± 0.50 2.17 ± 0.50 0.41
HR (b/min) 158 ± 14 157 ± 17 0.63
P (W) 169 ± 39 172 ± 38 0.45
VE (l/min) 55 ± 13 58 ± 14 0.26
Pre‑exercise Post‑exercise p value
BG (mmol/l) 9.3 ± 3.4 10 ± 3.2 0.06
Fig. 1 Relationships between  HbA1c and a  Timemax and b  VO2HRTP/PHRTP, n = 64
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economy is defined as the rate of oxygen use at a given 
workload. We found that individuals with poorer glycae-
mic control (higher  HbA1c values) displayed a higher rate 
of  O2 use at a sub-maximal work rate (HRTP) and ear-
lier  Timemax. This result is confirmed by the findings from 
Tagougui et al. in which the increase in deoxyhemoglobin 
(reflection of relative tissue deoxygenation) in the vastus 
lateralis was blunted in patients with T1D and with poor 
glycaemic control during CPX testing [20]. Interestingly, 
the maximum oxygen consumption was negatively corre-
lated with changes in deoxyhemoglobin.
Our findings are in contrast to recent studies evaluating 
the association between glycaemic control and functional 
capacity [6, 8]. Stubbe et al. could not find an association 
between  HbA1c levels and the  O2 uptake at the anaerobic 
lactate threshold [8]. This contrast in comparison to our 
results might explained by lower and more homogene-
ous  HbA1c levels as observed in our cohort. The variation 
in glycaemic control and its upper and lower extremes 
clearly contributed to the association between  HbA1c lev-
els and rates of  O2 use at the HRTP. Turinese et al. also 
did not find significant relationships between the glycae-
mic control and CPX derived markers [6]. However, the 
lack of associations might be originated by the low num-
ber of participants (N = 17).
There may be several postulated reasons for our find-
ings. During exercise, skeletal muscle consumes most of 
the inhaled  O2 and a greater  O2 cost for a given exercise 
intensity might indicate fibre atrophy and/or morpho-
logical abnormalities in the mitochondria [21]. Reduced 
skeletal muscle mitochondrial ATP production rates 
have also been associated with poor glycaemic control 
[22]. Furthermore, the capillary density surrounding 
skeletal muscle has been shown to be lower in individu-
als with T1D [23]. A reduced oxidative capacity within 
prime mover muscles increases dependence on support-
ing muscles, and increases the overall oxygen cost of the 
activity for a given workload. Furthermore, an earlier 
limit on  O2 use within a muscle shifts energy metabolism 
towards non-oxidative glycolysis and an earlier lowered 
pH [24]. Alternatively, oxygen supply systems may be 
compromised more in individuals with poorer glycaemic 
control. Red blood cell dynamics have been shown to be 
altered in T1D rats [25] with velocity and flux reduced 
in comparison to non-diabetics, albeit with a similar 
haematocrit.
People with T1D may display cardiomyopathy and this 
seems dependent on the  HbA1c value which has been 
hypothesised to alter cardiac structure, e.g. increased left 
ventricular wall thickness and mass, and impaired dias-
tolic function. Interestingly, poor glycaemic control was 
associated with reduced stroke volume and cardiac out-
put in athletes with T1D compared with non-diabetic 
individuals, despite an equivalent amount of training 
[26]. This reduction in stroke volume might be caused by 
earlier diastolic dysfunction, which reduces the atrioven-
tricular pressure gradient and causes early diastolic left 
ventricular filling [16].
The decreased economy at early stages during CPX 
testing translated to shorter exercise test duration. 
Indeed, approximately 55% of the shorter total exer-
cise time could be accounted for lowered  O2 uptake, 
decreased power output and less economical use of  O2 
for both at the HRTP and maximum power. Taken this 
into account, it might be that regular exercise training, 
which increases these physiological parameters, might 
have similar potential to neutralise the negative influence 
of glycaemic control on functional capacity [27] and even 
on cardiovascular autonomic regulation [28].
This study is limited by the heterogeneity and the wide 
range in the duration of diabetes, age, blood glucose 
concentration at the start of CPX testing and sex dis-
tribution. However, we addressed this limitation as we 
have adjusted for these factors. Additionally, it might 
be that different levels of blood glucose influenced 
Fig. 2 HbA1c quartiles for a  Timemax and b  VO2HRTP/PHRTP
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catecholamine response which in turn altered cardiac 
function during CPX testing.
Conclusions
In conclusion, in this well-characterised study, individu-
als with T1D and poorer glycaemic control displayed less 
economical use of oxygen at sub-maximal work rates and 
an earlier time to exhaustion during CPX testing. Nev-
ertheless, exercise training could have the same potential 
to counteract the influence of poor glycaemic control on 
functional capacity.
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